Survival and consolidative radiotherapy in patients living with HIV and treated for diffuse large B-cell lymphoma.

Autor:	Casimiro LC; Department of Radiation Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo Medical School, Brazil., Mauro GP; Department of Radiology and Oncology, University of Sao Paulo Medical School, School of Medicine, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.; Department of Radiology and Oncology, University of Sao Paulo Medical School, Brazil., Medici CTM; Department of Radiation Oncology, Barretos Cancer Hospital, Porto Velho, RO, Brazil., Weltman E; Department of Radiation Oncology, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.; Department of Radiology and Oncology, University of Sao Paulo Medical School, Brazil.
Jazyk:	angličtina
Zdroj:	Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2020 Nov-Dec; Vol. 25 (6), pp. 956-960. Date of Electronic Publication: 2020 Oct 01.
DOI:	10.1016/j.rpor.2020.09.004
Abstrakt:	Objectives: Current guidelines tend to treat HIV positive (HIV+) patients as their seronegative counterparts with diffuse large B-cell lymphoma (DLBCL) but little is known about their radiotherapy responses differences. Patients and Methods: A retrospective cohort of all consecutive HIV+ DBCL patients treated with chemotherapy between 2004 and 2018 was assessed. All patients had biopsy-proven lymphomas. They were included if the proposed radical treatment was done without progression or death during chemotherapy and had at least 6 months of follow-up or were followed until death. Results: Fifty-three (53) patients were selected, with a median age at diagnosis of 41.39 years (20-65 years). Median follow-up of 35.16 months (1.4-178.7 months). Male patients accounted for 54.7% and most had a good performance in the ECOG scale at diagnoses (81.1% are ECOG 0-1). Median overall survival was not reached. Mean OS was 41.5 months with 16 deaths. Age had an impact on OS, with patients older than 60 years at more risk (p = 0.044), as did longtime use of HAART, with those that started antiretroviral therapy within the diagnose of the lymphoma at greatest risk (p = 0.044). RT did not have an impact on OS (p = 0.384) or PFS (p = 0.420), although survival curves show better OS in the radiotherapy group. Toxicities were rare, since none of the patients had grade 3 or superior toxicity. Conclusion: RT did not impact survival or progression in our limited sample, but a longer OS may occur after the first-year post RT. RT should be tested in prospective data in the HIV+ population with DLBCL. (© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu